2-(bromomethyl)-4-carbethoxy-1,3-oxazole | 142841-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(bromomethyl)-4-carbethoxy-1,3-oxazole
• 英文别名: ethyl 2-(bromomethyl)-4-oxazolecarboxylate；4-Carboethoxy-2-(bromomethyl)oxazole；2-(bromomethyl)oxazole-4-carboxylic acid ethyl ester；2-[bromomethyl]-4-oxazolecarboxylic acid ethyl ester；ethyl 2-bromomethyloxazole-4-carboxylate；Ethyl 2-(bromomethyl)-1,3-oxazole-4-carboxylate
• CAS: 142841-00-7
• 化学式: C₇H₈BrNO₃
• 分子量: 234.049
• InChiKey: UIZIBTYIZFDYCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(bromomethyl)-4-carbethoxy-1,3-oxazole 在 sodium hydroxide 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 25.0h， 生成 2-[(8-chlorodibenz[b,f][1,4]oxazepin-10(11H)yl)methyl]-4-oxazole carboxylic acid
  参考文献：
  名称：

  2,4-Disubstituted oxazoles and thiazoles as latent pharmacophores for diacylhydrazine of SC-51089, a potent PGE2 antagonist

  摘要：

  8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[1-oxo-3-(4-pyridinyl)propyl]hydrazide monohydrochloride (1, SC-51089) is a functional PGE(2) antagonist selective for the EP1 receptor subtype with antinociceptive activity. (1,2) Analogues of SC-51089, in which the diacylhydrazine moiety has been replaced with 2,4-disubstituted-oxazoles and-thiazoles, are described. (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(00)00229-7
• 作为产物：
  描述：

  2-甲基-4-恶唑甲酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 以41%的产率得到2-(bromomethyl)-4-carbethoxy-1,3-oxazole
  参考文献：
  名称：

  A Macrolactamisation-Oxazoline Ring Forming Approach towards the tris-Oxazole Macrolide Core in the Ulapualides

  摘要：

  描述了一种新的设计用于合成25元三噁唑大环核3，这属于“乌拉普亚利德家族”的海洋天然产物，例如从海兔和海绵中分离出的1。该方法基于大环内酰胺化策略，生成4，随后使用取代的单噁唑5和6作为关键前体形成噁唑啉和噁唑环。

  DOI：

  10.1055/s-1999-2671

文献信息

• CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120095040A1

  公开（公告）日：2012-04-19

  The invention relates to compounds of the general formula (I) where: R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, or NR 8 R 9 group; m, n, o and p independently are a number from 0 to 3; A is a covalent bond, an oxygen atom, a C 1-6 -alkylene group or a —O—C 1-6 -alkylene group in which the end that is an oxygen atom is bonded to the R 1 group while the end that is an alkylene group is bonded to the carbon of the bicyclic compound; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl or trifluoromethyl group; R 4 is an optionally substituted 5-membered heterocyclic compound; wherein the compounds can be in the state of a base or an acid addition salt. The invention can be used in therapeutics.

  该发明涉及一般式（I）的化合物，其中：R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；m、n、o和p独立地是从0到3的数字；A是共价键、氧原子、C1-6-烷基烯基团或—O—C1-6-烷基烯基团，其中一个端是氧原子与R1基团结合，而另一个端是烷基烯基团与双环化合物的碳结合；R1是可选择取代的芳基或杂环芳基；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；其中这些化合物可以处于碱性或酸性盐的状态。该发明可用于治疗学。
• [EN] TETRAHYDROCARBAZOLES AND DERIVATIVES<br/>[FR] TETRAHYDROCARBAZOLES ET DERIVES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005092856A1

  公开（公告）日：2005-10-06

  The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRß agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在描述和权利要求中有定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物对于治疗和预防由LXRα和/或LXRß激动剂调节的疾病是有用的，包括增加的脂质和胆固醇水平，特别是低HDL-胆固醇、高LDL-胆固醇、动脉粥样硬化疾病、糖尿病，特别是非胰岛素依赖型糖尿病，代谢综合征，血脂异常，阿尔茨海默病，败血症，炎症性疾病如结肠炎、胰腺炎、肝胆瘀积/肝纤维化，以及具有炎症成分的疾病，如阿尔茨海默病或认知功能受损/可改善的疾病。
• Azepine derivatives useful as nitric oxide synthase inhibitors
  申请人：G. D. Searle & Co.

  公开号：US05883251A1

  公开（公告）日：1999-03-16

  The current invention discloses azepine derivatives useful as nitric oxide synthase inhibitors.

  当前发明揭示了作为一氧化氮合酶抑制剂有用的环庚烯衍生物。
• Rhodium-catalyzed heterocycloaddition route to 1,3-oxazoles as building blocks in natural products synthesis
  作者：Richard D. Connell、Mark Tebbe、Anthony R. Gangloff、Paul Helquist、Björn Åkermark

  DOI：10.1016/s0040-4020(01)87261-6

  日期：——

  Rhodium(II) acetate serves as a catalyst for the heterocycloaddition reaction of diazodicarbonyl compounds with nitriles to give functionalized 1,3-oxazole derivatives in a simple one-step procedure. In particular, dimethyl diazomalonate undergoes this reaction to give 2-aryl-, 2-alkenyl-, or 2-alkyl-4-carbomethoxy-5-methoxy-1,3-oxazoles, and ethyl formyldiazoacetate (diazomalonate half-ester half-aldehyde)

  乙酸铑（II）用作重氮二羰基化合物与腈的杂环加成反应的催化剂，可通过简单的一步过程即可得到官能化的1,3-恶唑衍生物。特别地，重氮丙二酸二甲酯经历该反应以产生2-芳基-，2-烯基-或2-烷基-4-羰基甲氧基-5-甲氧基-1,3-恶唑和甲酰基重氮乙酸乙酯（重氮丙二酸酯半酯半醛）得到2-芳基-，2-烯基-或2-烷基-4-羰基乙氧基-1,3-恶唑。这些产物作为重要的中间体，在合成几种含恶唑的天然产物和其他杂环系统中具有潜在的重要性。
• Towards a total synthesis of ulapualide A. Concise synthetic routes to the tris-oxazole ring system and tris-oxazole macrolide core in ulapualides, kabiramides, halichondramides, mycalolides and halishigamides
  作者：Shital K. Chattopadhyay、James Kempson、Alan McNeil、Gerald Pattenden、Michael Reader、David E. Rippon、David Waite

  DOI：10.1039/b000750l

  日期：——

  the synthesis of mono-, bis- and tris-2,4-disubstituted oxazoles were evaluated, which led ultimately to a concise synthesis of the three contiguous oxazole ring system 26 in the ulapualide family of 25-membered macrolides, e.g.1, found in marine organisms. The tris-oxazole macrolide core 30 in ulapualide A (1) was also synthesised based on a macrolactamisation strategy from the two functionalised mono-oxazole

  一系列合成单，双和三，2,4-二取代的方法 恶唑类被评估，最终导致25个成员的ulapualide家族中三个连续的恶唑环系统26的简明合成大环内酯类，例如1，存在于海洋生物中。ulapualide A（1）中的tris- oxazole大环内酯类药物核心30也基于大内酰胺化策略从两种功能化化合物中合成而成。一恶唑前体28和29，其次是恶唑啉 45和恶唑环的形成，利用在18和26的形成中线性双-和三-恶唑的合成中建立的方法。将三恶唑26转化为相应的phospho盐5，以准备将其制成乌拉泊肽A（1）。

表征谱图